Table 3 Open in new tab Antibodies in... | Oxford Academic

Table 3

Open in new tab

Antibodies in development for the treatment of SLE targeting T-cell surface antigens: comparison and analysis

Antibody	Ruplizumab	Toralizumab	Dapirolizumab pegol	AMG 557
Target	CD40L			ICOS
Efficiency	Reduction of the SLEDAI and improvement of clinical indicators of SLE.	Did not meet the study’s primary endpoints.	Improved clinical indicators of SLE but did not meet the primary endpoint of BICLA.	Improvement of BILAG and SLEDAI indices. Withdrawal of immunosuppressants and reduction of corticosteroids.
Safety	There is a high probability of developing thromboembolism as a result of aggregation of these antibodies with autoantibodies through the Fc gamma receptor.		Mild to moderate AEs, there were no cases of thromboembolism due to Fc site replacement with PEG.	Mild to moderate AEs.
Future prospects	Significant modification of the Fc receptor is required to prevent the risk of thromboembolism.	Low effectiveness and the risk of developing severe AEs do not motivate further research.	It is possible to modify the study design and evaluate effectiveness based on other indices.	High potential for conducting phase II and III clinical trials.

Antibody	Ruplizumab	Toralizumab	Dapirolizumab pegol	AMG 557
Target	CD40L			ICOS
Efficiency	Reduction of the SLEDAI and improvement of clinical indicators of SLE.	Did not meet the study’s primary endpoints.	Improved clinical indicators of SLE but did not meet the primary endpoint of BICLA.	Improvement of BILAG and SLEDAI indices. Withdrawal of immunosuppressants and reduction of corticosteroids.
Safety	There is a high probability of developing thromboembolism as a result of aggregation of these antibodies with autoantibodies through the Fc gamma receptor.		Mild to moderate AEs, there were no cases of thromboembolism due to Fc site replacement with PEG.	Mild to moderate AEs.
Future prospects	Significant modification of the Fc receptor is required to prevent the risk of thromboembolism.	Low effectiveness and the risk of developing severe AEs do not motivate further research.	It is possible to modify the study design and evaluate effectiveness based on other indices.	High potential for conducting phase II and III clinical trials.

Table 3

Open in new tab

Antibodies in development for the treatment of SLE targeting T-cell surface antigens: comparison and analysis

Antibody	Ruplizumab	Toralizumab	Dapirolizumab pegol	AMG 557
Target	CD40L			ICOS
Efficiency	Reduction of the SLEDAI and improvement of clinical indicators of SLE.	Did not meet the study’s primary endpoints.	Improved clinical indicators of SLE but did not meet the primary endpoint of BICLA.	Improvement of BILAG and SLEDAI indices. Withdrawal of immunosuppressants and reduction of corticosteroids.
Safety	There is a high probability of developing thromboembolism as a result of aggregation of these antibodies with autoantibodies through the Fc gamma receptor.		Mild to moderate AEs, there were no cases of thromboembolism due to Fc site replacement with PEG.	Mild to moderate AEs.
Future prospects	Significant modification of the Fc receptor is required to prevent the risk of thromboembolism.	Low effectiveness and the risk of developing severe AEs do not motivate further research.	It is possible to modify the study design and evaluate effectiveness based on other indices.	High potential for conducting phase II and III clinical trials.

Antibody	Ruplizumab	Toralizumab	Dapirolizumab pegol	AMG 557
Target	CD40L			ICOS
Efficiency	Reduction of the SLEDAI and improvement of clinical indicators of SLE.	Did not meet the study’s primary endpoints.	Improved clinical indicators of SLE but did not meet the primary endpoint of BICLA.	Improvement of BILAG and SLEDAI indices. Withdrawal of immunosuppressants and reduction of corticosteroids.
Safety	There is a high probability of developing thromboembolism as a result of aggregation of these antibodies with autoantibodies through the Fc gamma receptor.		Mild to moderate AEs, there were no cases of thromboembolism due to Fc site replacement with PEG.	Mild to moderate AEs.
Future prospects	Significant modification of the Fc receptor is required to prevent the risk of thromboembolism.	Low effectiveness and the risk of developing severe AEs do not motivate further research.	It is possible to modify the study design and evaluate effectiveness based on other indices.	High potential for conducting phase II and III clinical trials.